Mesoblast Ltd. (MESO)
13.82
-0.46
(-3.26%)
USD |
NASDAQ |
Jun 10, 16:00
13.82
0.00 (0.00%)
After-Hours: 20:00
Mesoblast Enterprise Value : 1.271B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 1.271B |
| June 08, 2026 | 1.229B |
| June 05, 2026 | 1.242B |
| June 04, 2026 | 1.326B |
| June 03, 2026 | 1.291B |
| June 02, 2026 | 1.291B |
| June 01, 2026 | 1.320B |
| May 29, 2026 | 1.367B |
| May 28, 2026 | 1.312B |
| May 27, 2026 | 1.303B |
| May 26, 2026 | 1.324B |
| May 22, 2026 | 1.350B |
| May 21, 2026 | 1.331B |
| May 20, 2026 | 1.291B |
| May 19, 2026 | 1.294B |
| May 18, 2026 | 1.302B |
| May 15, 2026 | 1.332B |
| May 14, 2026 | 1.339B |
| May 13, 2026 | 1.309B |
| May 12, 2026 | 1.284B |
| May 11, 2026 | 1.290B |
| May 08, 2026 | 1.310B |
| May 07, 2026 | 1.315B |
| May 06, 2026 | 1.402B |
| May 05, 2026 | 1.400B |
| Date | Value |
|---|---|
| May 04, 2026 | 1.418B |
| May 01, 2026 | 1.396B |
| April 30, 2026 | 1.390B |
| April 29, 2026 | 1.380B |
| April 28, 2026 | 1.351B |
| April 27, 2026 | 1.361B |
| April 24, 2026 | 1.376B |
| April 23, 2026 | 1.375B |
| April 22, 2026 | 1.396B |
| April 21, 2026 | 1.434B |
| April 20, 2026 | 1.471B |
| April 17, 2026 | 1.458B |
| April 16, 2026 | 1.426B |
| April 15, 2026 | 1.397B |
| April 14, 2026 | 1.299B |
| April 13, 2026 | 1.307B |
| April 10, 2026 | 1.332B |
| April 09, 2026 | 1.294B |
| April 08, 2026 | 1.240B |
| April 07, 2026 | 1.220B |
| April 06, 2026 | 1.321B |
| April 02, 2026 | 1.316B |
| April 01, 2026 | 1.401B |
| March 31, 2026 | 1.365B |
| March 30, 2026 | 1.278B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Propanc Biopharma, Inc. | 2.337M |
| Telix Pharmaceuticals Ltd. | 3.077B |
| Amplia Therapeutics Ltd. | 6.462M |
| Immutep Ltd. | -- |
| Fate Therapeutics, Inc. | 122.88M |
Enterprise Value Related Metrics
| Earnings Yield | -5.34% |
| Normalized Earnings Yield | -5.320 |